Linder Katharina, Zia Mutaher, Kern Winfried V, Pfau Ruth K M, Wagner Dirk
Centre for Infectious Diseases and Travel Medicine, University of Freiburg, Freiburg, Germany.
Trop Med Int Health. 2008 Mar;13(3):295-309. doi: 10.1111/j.1365-3156.2008.02003.x.
To compare a new scoring system for multibacillary (MB) leprosy relapses, which combines time factor, risk factors and clinical presentation at relapse, to WHO criteria.
Data were collected on all relapses diagnosed between 1998 and 2004 at the Marie-Adelaide-Centre in Karachi, Pakistan, including case histories, clinical manifestations, follow-up, bacterial indices, treatment and contacts. For the diagnosis of MB relapses a simple scoring system was developed and validated on a data-set of mouse foot pads (MFP)-confirmed relapses (Leprosy Reviews, 76, 2005, 241). Its sensitivity was further evaluated in the Karachi relapse cohort. The P-value was calculated with McNemar's test with continuity correction.
The new scoring system that combines time factor, risk factors and clinical presentation at relapse had a higher sensitivity in MFP-confirmed relapses than the WHO-criteria (95%vs. 65%, P < 0.01). The sensitivity of the scoring system was also significantly higher than the WHO criteria in the 57 cases of MB-relapses diagnosed in Karachi (72%vs. 54%, P < 0.05).
This new simple scoring system for diagnosing MB-relapses in leprosy should be further validated in a prospective study to confirm its superior sensitivity and to evaluate the specificity of these criteria by using MFP-confirmation for patients presenting with signs of activity after treatment.
比较一种用于多菌型(MB)麻风复发的新评分系统与世界卫生组织(WHO)标准,该新评分系统综合了时间因素、风险因素以及复发时的临床表现。
收集了1998年至2004年期间在巴基斯坦卡拉奇的玛丽 - 阿德莱德中心诊断的所有复发病例的数据,包括病史、临床表现、随访情况、细菌指数、治疗情况及接触者情况。为诊断MB复发,开发了一种简单的评分系统,并在一组经小鼠足垫(MFP)确认的复发数据集上进行了验证(《麻风病评论》,76卷,2005年,第241页)。在卡拉奇复发队列中进一步评估了其敏感性。使用连续性校正的McNemar检验计算P值。
综合时间因素、风险因素和复发时临床表现的新评分系统在经MFP确认的复发中比WHO标准具有更高的敏感性(95%对65%,P < 0.01)。在卡拉奇诊断的57例MB复发病例中,该评分系统的敏感性也显著高于WHO标准(72%对54%,P < 0.05)。
这种用于诊断麻风MB复发的新的简单评分系统应在前瞻性研究中进一步验证,以确认其更高的敏感性,并通过对治疗后出现活动迹象的患者使用MFP确认来评估这些标准的特异性。